Bionest

Running the Risks of High Stakes Drug Development

On August 5, Bristol-Myers Squibb (BMS) surprised many with the announcement that their PD-L1 inhibitor Opdivo® (nivolumab) had failed a Phase 3 trial assessing its use as a monotherapy in the first-line treatment of non-small cell lung cancer (NSCLC). This is a disease where the drug is already approved and used in patients who have failed prior...

Bionest

Update on the “Cancer Moonshot”

In March, we wrote about the “Cancer Moonshot” Initiative that was announced as part of President Obama’s 2016 State of the Union Address. Headed by Vice President Joe Biden, the aim of the initiative was to facilitate collaboration in cancer research, treatment, detection and prevention and to facilitate a decade’s worth of advances over the...